, Tracking Stock Market Picks
Enter Symbol:

up 1,476.54 %

MEDIVATION INC (MDVN) upgraded to Buy with price target $14 by Roth Capital

Posted on: Monday,  Apr 26, 2010  8:25 AM ET by Roth Capital

Roth Capital rated Buy MEDIVATION INC (NASDAQ: MDVN) on 04/26/2010, when the stock price was $5.84. Since
then, MEDIVATION INC has gained 1476.54% as of 01/27/2016's recent price of $92.07.
If you would have followed this Roth Capital's recommendation on MDVN, you would have gained 1476.54% of your investment in 2102 days.

Medivation, Inc. is a biopharmaceutical company with small molecule drugs in clinical development to treat three medical needs: Alzheimer?s disease, Huntington?s disease and castration-resistant prostate cancer. The Company has formed separate subsidiaries to hold the product candidates it is developing. The Company?s subsidiary Medivation Neurology, Inc. holds its Dimebon technology, and its subsidiary Medivation Prostate Therapeutics, Inc. holds its MDV300 series technology.

ROTH researches emerging growth equities in the media, technology, telecommunications, healthcare, consumer, energy and industrial sectors. The research is focused on companies with market capitalization of between $100 million - $1 billion. Our coverage universe includes approximately 180 small cap growth companies around the globe including several companies from China. With an average market cap of approximately $500 million, our objective is to identify rapidly growing companies with significant long term growth prospects.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/26/2010 8:25 AM Buy
5.84 7.00
as of 12/31/2010
1 Week down  -9.46 %
1 Month up  27.53 %
3 Months up  11.15 %
1 YTD down  -42.02 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/3/2010 9:25 AM Hold
6.45 5.00
11/5/2009 9:25 AM Buy
13.43 17.00
2/26/2009 8:25 AM Hold
11/11/2008 8:25 AM Buy
9.30 11.50
9/4/2008 8:25 AM Buy
14.81 18.50
1/17/2008 8:25 AM Buy
7.68 10.50

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy